CLINICAL TRIALS PROFILE FOR ORSERDU
✉ Email this page to a colleague
All Clinical Trials for orserdu
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT05963997 ↗ | A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer | Recruiting | Berlin-Chemie AG Menarini Group | Phase 1/Phase 2 | 2023-10-09 | This is an international, multisite, open-label, Phase 1b/2 study, to confirm safety and efficacy of samuraciclib in combination with elacestrant in adult participants with metastatic or locally advanced Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor (HER)2-negative breast cancer. |
NCT05963997 ↗ | A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer | Recruiting | Carrick Therapeutics Limited | Phase 1/Phase 2 | 2023-10-09 | This is an international, multisite, open-label, Phase 1b/2 study, to confirm safety and efficacy of samuraciclib in combination with elacestrant in adult participants with metastatic or locally advanced Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor (HER)2-negative breast cancer. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for orserdu
Condition Name
Clinical Trial Locations for orserdu
Trials by Country
Clinical Trial Progress for orserdu
Clinical Trial Phase
Clinical Trial Sponsors for orserdu
Sponsor Name